Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma

Authors

Benjamin M Ellingson, University of California, Los Angeles
Jian L Campian, Washington University School of Medicine in St. Louis
et al.

Journal

Neuro-Oncology Advances

Publication Date

1-1-2021

Volume

3

Issue

1

First Page

vdab082

Document Type

Open Access Publication

DOI

10.1093/noajnl/vdab082

Rights and Permissions

Benjamin M Ellingson, Kunal Patel, Chencai Wang, Catalina Raymond, Andrew Brenner, John F de Groot, Nicholas A Butowski, Leor Zach, Jian L Campian, Jacob Schlossman, Shan Rizvi, Yael C Cohen, Noa Lowenton-Spier, Tamar Rachmilewitz Minei, Shifra Fain Shmueli, Patrick Y Wen, Timothy F Cloughesy, Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma, Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab082, https://doi.org/10.1093/noajnl/vdab082. © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

Recommended Citation

Ellingson, Benjamin M; Campian, Jian L; and et al., "Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma." Neuro-Oncology Advances. 3, 1. vdab082 (2021).
https://digitalcommons.wustl.edu/oa_4/760